Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Havaintotutkimus nesteen erottuvuuden ja tehokkuuden arvioimiseksi potilailla, jotka saavat Beovua uudissuonien ikään liittyvässä silmänpohjan rappeutumassa (BLUE SKY)

tiistai 17. marraskuuta 2026 päivittänyt: Novartis Pharmaceuticals

HavainnointitutkiMus nesteen erottuvuuden ja tehokkuuden arvioimiseksi potilailla, jotka saavat beovu-hoitoa (brolutsisumabia) uusiovaskulaarisen ikään liittyvän silmänpohjan rappeuman tärkeimpien hoitojärjestelmien mukaisesti

This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.

An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".

Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.

All patients were documented either in the AMD or DME-module (Full Analysis Set).

For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Todellinen)

572

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Aschersleben, Saksa, 06449
        • Novartis Investigative Site
      • Bayreuth, Saksa, 95445
        • Novartis Investigative Site
      • Berlin, Saksa, 10713
        • Novartis Investigative Site
      • Berlin, Saksa, 14163
        • Novartis Investigative Site
      • Bonn, Saksa, 53105
        • Novartis Investigative Site
      • Breisach, Saksa, 79206
        • Novartis Investigative Site
      • Chemnitz, Saksa, 09113
        • Novartis Investigative Site
      • Cologne, Saksa, 50968
        • Novartis Investigative Site
      • Dresden, Saksa, 01067
        • Novartis Investigative Site
      • Dresden, Saksa, 01324
        • Novartis Investigative Site
      • Esslingen am Neckar, Saksa, 73728
        • Novartis Investigative Site
      • Glauchau, Saksa, 08371
        • Novartis Investigative Site
      • Homburg, Saksa, 66421
        • Novartis Investigative Site
      • Hösbach, Saksa, 63768
        • Novartis Investigative Site
      • Kiel, Saksa, 24103
        • Novartis Investigative Site
      • Leipzig, Saksa, 04106
        • Novartis Investigative Site
      • Magdeburg, Saksa, 39104
        • Novartis Investigative Site
      • Marienberg, Saksa, 09496
        • Novartis Investigative Site
      • Münster, Saksa, 48145
        • Novartis Investigative Site
      • Neubrandenburg, Saksa, 17036
        • Novartis Investigative Site
      • Schönebeck, Saksa, 39218
        • Novartis Investigative Site
      • Stralsund, Saksa, 18435
        • Novartis Investigative Site
      • Sulzbach, Saksa, 66280
        • Novartis Investigative Site
      • Torgau, Saksa, 04860
        • Novartis Investigative Site
      • Waren, Saksa, 17192
        • Novartis Investigative Site
      • Würzburg, Saksa, 97080
        • Novartis Investigative Site
    • Bavaria
      • Munich, Bavaria, Saksa, 81377
        • Novartis Investigative Site
      • Neuburg A.d. Donau, Bavaria, Saksa, 86633
        • Novartis Investigative Site
      • Würzburg, Bavaria, Saksa, 97080
        • Novartis Investigative Site
      • Würzburg, Bavaria, Saksa, 97070
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Saksa, 60590
        • Novartis Investigative Site
    • Lower Saxony
      • Göttingen, Lower Saxony, Saksa, 37075
        • Novartis Investigative Site
      • Osnabrück, Lower Saxony, Saksa, 49076
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Rostock, Mecklenburg-Vorpommern, Saksa, 18057
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Trier, Rhineland-Palatinate, Saksa, 54296
        • Novartis Investigative Site
    • Saarland
      • Saarbrücken, Saarland, Saksa, 66111
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Saksa, 01307
        • Novartis Investigative Site
      • Leipzig, Saxony, Saksa, 04103
        • Novartis Investigative Site
      • Schneeberg, Saxony, Saksa, 08289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Saksa, 06118
        • Novartis Investigative Site
    • Thuringia
      • Jena, Thuringia, Saksa, 07740
        • Novartis Investigative Site

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 99 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.

Kuvaus

Inclusion Criteria:

The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:

  1. Diagnosis of nAMD or visual impairment due to DME
  2. Male and Female nAMD and DME patients with ≥18 years of age at index
  3. Decision to treat with brolucizumab at baseline visit
  4. Signed written informed consent
  5. Patients for whom a therapy with brolucizumab was medically indicated
  6. Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening

Exclusion Criteria:

  1. Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
  2. Patients treated for RVO or CNV other than nAMD
  3. Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
  4. Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
  5. Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
  6. Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
  7. Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
  8. Patients participating in parallel in an interventional clinical trial
  9. Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
  10. Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
  11. Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
  12. Pregnancy and breast-feeding

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: COHORT
  • Aikanäkymät: PROSPECTIVE

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
treatment naïve patients

Patients being the first time treated for nAMD or DME

There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

pre-treated patients

Patients already being treated for nAMD or DME

There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
Aikaikkuna: Month 12

This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch).

Month 12
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
Aikaikkuna: Baseline, month 12

This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.

Baseline, month 12
Morphological CNV-Changes under clinic specific routine treatment schemes
Aikaikkuna: Baseline, month 12

This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.

Baseline, month 12
Percent of patients maintained on q12w dosing after loading through Week 52
Aikaikkuna: After loading, month 12

This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study.

After loading, month 12
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
Aikaikkuna: Baseline, month 12

This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes.

Baseline, month 12

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
Aikaikkuna: Baseline

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline
Evaluate anatomical parameters during treatment with brolucizumab
Aikaikkuna: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Up to month 24
Evaluate VA change from baseline during treatment with brolucizumab
Aikaikkuna: Baseline, month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Baseline, month 24
Estimate number of anti-VEGF injections, visits and injection intervals
Aikaikkuna: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate percentage of switchers during first 6 months and characterize switchers
Aikaikkuna: Baseline, month 6

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline, month 6
Estimate discontinuation rate and time to discontinuation
Aikaikkuna: Month 1-12 and 13-24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Assess retreatment criteria
Aikaikkuna: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate the number of OCT
Aikaikkuna: Month 1-12 and 13-24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Assess the safety of brolucizumab
Aikaikkuna: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate anatomical effectiveness
Aikaikkuna: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate treatment intervals
Aikaikkuna: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Describe implementation of treatment schemes into clinical practice
Aikaikkuna: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
Aikaikkuna: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
Aikaikkuna: Month 12

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 12
Evaluate anatomical parameters during treatment with brolucizumab
Aikaikkuna: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Characterize VA change from baseline during treatment with brolucizumab
Aikaikkuna: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Estimate discontinuation rate during first year of brolucizumab treatment
Aikaikkuna: Baseline, month 12

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline, month 12
Estimate time to discontinuation (persistence)
Aikaikkuna: Up to month 24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate the treatment burden
Aikaikkuna: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Estimate the number of OCT and the number of visits with/without OCT
Aikaikkuna: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Month 1-12 and 13-24
Assess safety of brolucizumab
Aikaikkuna: Up to month 24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Up to month 24

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Opintojohtaja: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 18. maaliskuuta 2020

Ensisijainen valmistuminen (Todellinen)

Maanantai 17. marraskuuta 2025

Opintojen valmistuminen (Todellinen)

Maanantai 17. marraskuuta 2025

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 4. syyskuuta 2020

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 4. syyskuuta 2020

Ensimmäinen Lähetetty (Todellinen)

Torstai 10. syyskuuta 2020

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 20. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 17. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • CRTH258ADE02

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa